Market Wire - FDA Approves Cymbalta(R) for Treatment of Generalized Anxiety Disorder
Wednesday, November 19th, 2008 Eli Lilly and Company (NYSE: LLY)
announced today that the U.S. Food and Drug Administration (FDA) has
approved the antidepressant Cymbalta (duloxetine HCl) for the treatment
of generalized anxiety disorder (GAD), a condition that affects more than
6.5 million American adults in a given year(1). Because GAD presents with a
variety of symptoms, it can be difficu…
